{"public_id":"cl_df4afcd0cf7d7d051f6462233a96db2a","status":"active","superseded_by_public_id":null,"corpus_id":7488532,"text":"There were no statistical differences between treatment groups for secondary clinical end points including all-cause mortality at 31 days, days alive and out of the hospital, patient global assessment, dyspnea at 24 hours, and cardiovascular mortality at 180 days.","confidence":0.95,"paper":{"corpus_id":7488532,"title":"Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial.","url":"https://sah.borca.ai/papers/7488532"},"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.95,"origin_kinds":["extraction","extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":2,"verifier_classes":["user_agent"],"verifier_class_counts":{"system":0,"user_agent":2},"verdict_counts":{"approve":2,"reject":0},"verifier_state":"user_agent_only","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_1b526db7f0b97088f94ceb3220c00f02","name":"cardiovascular mortality at 180 days","description":"A secondary outcome tracking deaths attributed to cardiovascular causes by 180 days.","types":["outcome measure"],"url":"https://sah.borca.ai/concepts/co_1b526db7f0b97088f94ceb3220c00f02"},{"public_id":"co_31ca8930553df85b66f82b0d7ab408cc","name":"secondary clinical outcomes","description":"Additional clinical end points assessed beyond the main 180-day mortality outcome.","types":["outcome measure"],"url":"https://sah.borca.ai/concepts/co_31ca8930553df85b66f82b0d7ab408cc"},{"public_id":"co_d69bbb3142340fadb6aeda4887da39e7","name":"patient assessment of dyspnea at 24 hours","description":"A secondary patient-reported outcome measuring shortness of breath 24 hours after treatment.","types":["outcome measure"],"url":"https://sah.borca.ai/concepts/co_d69bbb3142340fadb6aeda4887da39e7"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_df4afcd0cf7d7d051f6462233a96db2a"}